Literature DB >> 22820415

Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

Danielle A A Hollman1, Alexandra Milona, Karel J van Erpecum, Saskia W C van Mil.   

Abstract

The farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear receptor (NR) superfamily. FXR plays an important role in positively regulating genes (transactivation) involved in bile acid homeostasis, fat and glucose metabolism. Recently, it has become clear that an additional important role for FXR consists of downregulating genes involved in inflammation. Because of this broad spectrum of regulated genes, therapeutically targeting FXR with full agonists will likely result in adverse side effects, in line with what is described for other NRs. It may therefore be necessary to develop selective FXR modulators. However, the molecular mechanisms that distinguish between FXR-mediated transactivation and transrepression are currently unknown. For other NRs, post-translational modifications such as SUMOylation and phosphorylation have been reported to be unique to either transactivation or transrepression. Here, we review current knowledge on post-translational regulation of FXR with respect to transactivation and transrepression. Ultimately, increased understanding of the different mechanisms of transactivation and transrepression of nuclear receptors will aid in the development of NR drugs with fewer side effects.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820415     DOI: 10.1016/j.bbalip.2012.07.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

2.  A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR.

Authors:  Stéphanie Bilodeau; Véronique Caron; Jonathan Gagnon; Alexandre Kuftedjian; André Tremblay
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

3.  Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.

Authors:  Antonella Giancristofaro; Arménio J M Barbosa; Alessandra Ammazzalorso; Pasquale Amoia; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Cristina Maccallini; Rosa Amoroso
Journal:  Medchemcomm       Date:  2018-07-04       Impact factor: 3.597

4.  Pregnane X receptor modulates the inflammatory response in primary cultures of hepatocytes.

Authors:  Mengxi Sun; Wenqi Cui; Sarah K Woody; Jeff L Staudinger
Journal:  Drug Metab Dispos       Date:  2014-12-19       Impact factor: 3.922

Review 5.  FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.

Authors:  Rotonya M Carr; Andrea E Reid
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 6.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

8.  Poly(ADP-ribose) polymerase 1 promotes oxidative-stress-induced liver cell death via suppressing farnesoid X receptor α.

Authors:  Cheng Wang; Fengxiao Zhang; Lin Wang; Yanqing Zhang; Xiangrao Li; Kun Huang; Meng Du; Fangmei Liu; Shizheng Huang; Youfei Guan; Dan Huang; Kai Huang
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

9.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

10.  Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.

Authors:  Xiaoying Liu; Grace L Guo; Bo Kong; David B Hilburn; Susan C Hubchak; Seong Park; Brian LeCuyer; Antony Hsieh; Li Wang; Deyu Fang; Richard M Green
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.